ISRCTN82088636已完成2 期
A double-blind placebo controlled crossover study to determine if 1.5 and 3.0 mg of APL510 can normalise sleep patterns in elderly subjects with difficulty in maintenance of sleep and/or initiating sleep onset
Alliance Pharmaceuticals Ltd (UK)0 个研究点目标入组 80 人开始时间: 2010年1月15日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Male or female subjects aged 65 years or more presenting with self-reported poor sleep quality defined as at least two of the following:
- •1.1. Regularly took more than 45 minutes to fall asleep (at least three nights per week)
- •1.2. Overall night-time sleep less than 5 hours on at least 3 nights per week
- •1.3. Regular night-time awakenings defined as at least twice per night on at least 3 nights per week
- •2. Subjects with a poor sleep quality for at least 8 weeks
- •3. Written informed consent
排除标准
- •1. Had a clinically significant unstable medical abnormality, chronic disease or history or presence of significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, psychiatric, metabolic disease or malignancy which in the opinion of the investigator would have precluded successful participation in the study
- •2. Had a recent history of (less than 2 years) alcohol or drug abuse or current evidence of substance dependence or abuse as defined by the Diagnostic and Statistical Manual of Mental Disorders-IV criteria
- •3. Had major depression or anxiety causing sleep disturbance as defined by Diagnostic and Statistical Manual of Mental Disorders-IV criteria
- •4. Had a clinically significant illness within the last 30 days
- •5. Routine biochemistry parameters (e.g., creatinine or liver function tests) greater than 2 x the upper limit of normal for this age of population. Haemoglobin less than 10 g/dL.
- •6. Subjects receiving B6 or B12 supplements (multivitamin supplements were allowable provided intake did not exceed the recommended daily dose)
- •7. Subjects receiving warfarin or other vitamin K antagonists
- •8. Subjects planning to travel through more than two time zones whilst entered into the study
- •9. Subjects with a known hypersensitivity to melatonin or any of the excipients in the formulation
- •10. Subjects who, by virtue of the need to care for a close family member, were subjected to intermittent night-time disturbance
- •11. Subjects who had experienced the bereavement of a close family member within the last 3 months
- •12. Subjects who had used any other investigational drug within the last 30 days
- •13. Subjects planning to work night shifts
- •14. Subjects on treatment with anxiolytics, antidepressants, anticonvulsants, hypnotics or strong narcotic analgesics within the last 30 days. Other narcotic analgesics were allowed if they had been used at a constant dose for at least the last 30 days, the dose was unlikely to change during the duration of the study and in the opinion of the investigator, not likely to interfere with the subject's sleep quality. Subjects receiving hypnotics were eligible for the study if they consented to withdraw from treatment for 16 days prior to screening.
- •15. Subjects with a known severe allergic or auto-immune disease
- •16. Subjects with other conditions that may have caused night-time awakenings (e.g., nocturia or uncontrolled nocturnal pain) that in the investigator's opinion would have interfered with the assessment of the subject's sleep disturbance
- •17. Subjects who, in the opinion of the investigator, were unlikely to complete the study satisfactorily
- •Subjects were advised that caution was to be exercised when driving or operating any heavy or dangerous machinery within 6 hours of taking a dose of study medication.
研究者
相似试验
已完成
2 期
The use of APL510 to improve the length of day time sleep in subjects working permanent night-shiftsMental and Behavioural DisordersNonorganic sleep disordersInsomniaISRCTN15733268Alliance Pharmaceuticals Ltd (UK)44
进行中（未招募）
1 期
A double-blind placebo controlled cross-over study to determine if 1.5 and 3mg of APL510 can normalise sleep patterns in elderly subjects with difficulty in maintenance of sleep and/or initiating sleep onset. - N/AEUCTR2004-003939-32-GBAlliance Pharmaceuticals Ltd80
进行中（未招募）
不适用
A double blind placebo controlled crossover study to determine the effects of atomoxetine on event-related potentials in response to auditory oddball stimuli during an on-the-road driving test in adult patients with attention deficit hyperactivity disorder - Effects of atomoxetine on attention and driving in adult ADHDThe effects of atomoxetine on driving performance, attention and response inbihition are studied in adult patients with attention-deficit hyperactivity disorderEUCTR2007-001855-20-NLFaculty of Social Sciences, Utrecht University30
撤回
不适用
A double blind placebo-controlled crossover study to determine the effects of atomoxetine on event-related potentials in response to auditory oddball stimuli during an on-the-road driving test in adult patients with attention-deficit hyperactivity disorderADHD10009841Attention Deficit Hyperactivity DisorderNL-OMON31557niversiteit Utrecht30
进行中（未招募）
1 期
A double-blind placebo-controlled cross-over study to determine if melatonin can improve the length of day time sleep in subjects with transient misalignment of the sleep-wake cycle as a result of working permanent night shifts.Transient misalignment of the sleep-wake cycle as a result of working night shifts (insomnia in night shift workers)EUCTR2005-000120-17-GBAlliance Pharmaceuticals Ltd60